Literature DB >> 27454730

Committee Opinion No. 670 Summary: Immediate Postpartum Long-Acting Reversible Contraception.

.   

Abstract

Immediate postpartum long-acting reversible contraception (LARC) has the potential to reduce unintended and short-interval pregnancy. Women should be counseled about all forms of postpartum contraception in a context that allows informed decision making. Immediate postpartum LARC should be offered as an effective option for postpartum contraception; there are few contraindications to postpartum intrauterine devices and implants. Obstetrician-gynecologists and other obstetric care providers should discuss LARC during the antepartum period and counsel all pregnant women about options for immediate postpartum initiation. Education and institutional protocols are needed to raise clinician awareness and to improve access to immediate postpartum LARC insertion. Obstetrician-gynecologists and other obstetric care providers should incorporate immediate postpartum LARC into their practices, counsel women appropriately about advantages and risks, and advocate for institutional and payment policy changes to support provision.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27454730     DOI: 10.1097/AOG.0000000000001583

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  2 in total

1.  Expulsion of intrauterine devices after postpartum placement by timing of placement, delivery type, and intrauterine device type: a systematic review and meta-analysis.

Authors:  Sarah H Averbach; Yokabed Ermias; Gary Jeng; Kathryn M Curtis; Maura K Whiteman; Erin Berry-Bibee; Denise J Jamieson; Polly A Marchbanks; Naomi K Tepper; Tara C Jatlaoui
Journal:  Am J Obstet Gynecol       Date:  2020-03-03       Impact factor: 8.661

2.  Patterns of postpartum contraceptive use among Somali immigrant women living in Minnesota.

Authors:  Amy Millar; Rachel Isaksson Vogel; Sabrina Bedell; Maureen Ayers Looby; Jessica L Hubbs; Bernard L Harlow; Rahel Ghebre
Journal:  Contracept Reprod Med       Date:  2017-04-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.